Alborz is Co-Founder and President of Exavir Therapeutics and is dedicated to making a difference for the millions of patients who are at risk for or living with HIV / AIDS.
Prior to Exavir, Alborz was a SMiD-cap therapeutics-focused investor at Passaic Capital (Millennium Management) and Bain Capital Life Sciences, as well as a therapeutics-focused management consultant for large-cap pharmaceutical companies at the Boston Consulting Group.
Alborz graduated from Yale with a BS in Molecular Biophysics and Biochemistry, where he conducted research in the Department of Chemistry on multifunctional chimeric small molecules with therapeutic applications.